...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Due Dilligence
Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of the BET Bromodomain Inhibitor ZEN-3694
Posted by:
BearDownAZ
on
Jul 22, 2021 09:56AM
Triple Negative Breast Cancer Drug Development Digital Summit 4/29/2021
Posted by:
BearDownAZ
on
Jun 24, 2021 04:13PM
Zenith Epigenetics Links
Zenith's Eligibility for registered accounts in Canada
... first link contains info from company and the second link contains the docs explaining Zenith eligibility for RRSP's and TFSA's... c/o KBC & LongRVXer...
Posted by:
kelsee
on
Aug 20, 2018 12:02PM
Zenith AGM 12 Dec 2017 - Q&A
AGM and Q&A notes from Tada
Posted by:
BearDownAZ
on
Dec 19, 2017 11:06AM
BET inhibitors and breast cancer
A nice review on the past, present and future of BET inhibitors for treatment of various breast cancers
Posted by:
BearDownAZ
on
Nov 27, 2017 12:39PM
BIO Investor Forum 10/17/17... webcast transcript
... transcript by Imtesty from BIO Investor Forum
Posted by:
kelsee
on
Oct 26, 2017 10:45AM